Clinical Report: RAS(ON) Inhibitor Doubles Median Overall Survival

Overview

The RASolute 302 trial demonstrated that daraxonrasib, an investigational oral RAS(ON) inhibitor in phase 3 trials, significantly improves overall survival and progression-free survival in patients with previously treated metastatic pancreatic cancer compared to chemotherapy. This may establish a new standard of care for this patient population, pending FDA approval.

Background

Pancreatic cancer is often diagnosed at an advanced stage, leading to poor survival rates, with most patients surviving less than a year. Current treatment options primarily involve chemotherapy, which offers limited benefits. Notably, over 90% of patients with pancreatic cancer have KRAS mutations, making targeted therapies like daraxonrasib a potential shift in treatment paradigms for this challenging malignancy.

Data Highlights

Key Findings

• Daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with chemotherapy.
• Patients receiving daraxonrasib had a median progression-free survival of 7.2 months compared to 3.6 months for chemotherapy.
• The objective response rate was 31.6% for daraxonrasib versus 11.2% for chemotherapy.
• Among patients with RAS G12 mutations, 33.2% experienced significant tumor shrinkage with daraxonrasib.
• Daraxonrasib was well tolerated with manageable side effects, including rash, nausea, inflammation in the mouth, and diarrhea.

Clinical Implications

The findings from the RASolute 302 trial suggest that daraxonrasib could become a new standard of care for second-line treatment in metastatic pancreatic cancer, potentially improving patient outcomes significantly. Clinicians should consider this option for patients who have previously received chemotherapy, pending FDA approval.

Conclusion

Daraxonrasib represents a promising advancement in the treatment of metastatic pancreatic cancer, with the potential to enhance survival and quality of life for patients. Further studies and FDA approval could solidify its role in clinical practice.

Related Resources & Content

1. The ASCO Post, 2026 -- Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
2. The ASCO Post, 2026 -- RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
3. The ASCO Post, 2026 -- Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
4. The ASCO Post — Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
5. NCCN Guidelines for Pancreatic Cancer
6. Unraveling (K)RAS in pancreatic ductal adenocarcinoma
7. Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer - The ASCO Post